Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma

被引：7
|
作者：
Miron, Benjamin [1 ]
Geynisman, Daniel M. [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA USA
来源：
EUROPEAN UROLOGY | 2022年 / 82卷 / 04期
关键词：
CHEMOTHERAPY; CISPLATIN; MULTICENTER;
D O I：
10.1016/j.eururo.2022.05.023
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：374 / 376
页数：3
相关论文
共 50 条
  • [21] Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma
    Vitale, Maria Giuseppa
    Nasso, Cecilia
    Oltrecolli, Marco
    Baldessari, Cinzia
    Fanelli, Martina
    Dominici, Massimo
    Sabbatini, Roberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1183 - 1192
  • [22] Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
    Apolo, Andrea B.
    Michaels-Igbokwe, Christine
    Simon, Nicholas I.
    Benjamin, David J.
    Farrar, Mallory
    Hepp, Zsolt
    Mucha, Lisa
    Heidenreich, Sebastian
    Cutts, Katelyn
    Krucien, Nicolas
    Ramachandran, Natasha
    Gore, John L.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2025, 18 (01): : 77 - 87
  • [23] Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma
    Gartrell, Benjamin Adam
    Hahn, Noah M.
    Hutson, Thomas E.
    Sonpavde, Guru
    Hauke, Ralph J.
    Starodub, Alexander
    Small, Alexander C.
    Tsao, Che-Kai
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
    Barragan-Carrillo, Regina
    Chawla, Neal Shiv
    Salgia, Nicholas
    Meza, Luis A.
    Zengin, Zeynep Busra
    Li, Xiaochen
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Hsu, Joann
    Castro, Daniela V.
    Mercier, Benjamin D.
    Dorff, Tanya B.
    Tripathi, Abhishek
    Bergerot, Cristiane Decat
    Bergerot, Paulo Gustavo
    Chehrazi-Raffle, Alex
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS491 - TPS491
  • [25] Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma
    Bedke, J.
    Liao, W.
    Shi, L.
    Blum, S. I.
    Patel, M.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1134 - S1134
  • [26] NKTR-214+nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
    Siefker-Radtke, Arlene O.
    Fishman, Mayer N.
    Balar, Arjun Vasant
    Grignani, Giovanni
    Diab, Adi
    Gao, Jianjun
    Tagliaferri, Mary Ann
    Hannah, Alison L.
    Karski, Erin E.
    Zalevsky, Jonathan
    Hoch, Ute
    Rizwan, Ahsan Naqi
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [27] Optimising first-line treatment for metastatic renal cell carcinoma
    de Velasco, Guillermo
    LANCET, 2020, 395 (10219): : E7 - E7
  • [28] COST-EFFECTIVENESS OF AVELUMAB AS FIRST-LINE MAINTENANCE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN FINLAND
    Karttunen, E.
    Jaaskelainen, S.
    Hervonen, P.
    Chang, J.
    Kearney, M.
    VALUE IN HEALTH, 2022, 25 (01) : S99 - S99
  • [29] Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma
    Cote, Gabrielle
    Alqaisi, Husam
    Chan, Christopher T.
    Jiang, Di Maria
    Kandel, Christopher
    Pelletier, Karyne
    Wald, Ron
    Sridhar, Srikala S.
    Kitchlu, Abhijat
    KIDNEY360, 2023, 4 (09): : 1203 - 1211
  • [30] Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma
    Liu, Tong
    Jin, Yao
    Dong, Mei
    CLINICAL GENITOURINARY CANCER, 2023, 21 (06) : E449 - E460
12345